MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA
Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.
Stocktwits
More News
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week?
Investor interest has focused on companies nearing key milestones, signing major partnerships, or improving their business outlook.
Stocktwits
Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more
Here are the companies making headlines in midday trading...
CNBC: Top News
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts
Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.
Zacks
Should You Buy Moderna Before Aug. 5?
Key PointsInvestors flocked to Moderna during early pandemic days as its coronavirus vaccine delivered blockbuster revenue...
Nasdaq News: Markets
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?
Key PointsModera grew revenue by 260% year over year in the first quarter...
Nasdaq News: Markets
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
Zacks
MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine
Jefferies noted that FDA decisions aligned with advisory committee recommendations 84% of the time between 2020 and 2025.
Stocktwits
Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF
Moderna shares have surged nearly 30% in five days, ahead of a key FDA advisory vote on its flu vaccine, lifting the leveraged MRNX ETF more than 60%.read more...
Benzinga
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
Moderna jumps after FDA briefing documents on mFlusiva appear more constructive than expected ahead of a key advisory panel review.